A retrospective study conducted at the University Health Network found that, in liver transplant recipients with diabetes, combination therapy reduced HbA1c and alanine aminotransferase levels more effectively than DPP-4 inhibitors. Additionally, two clinical trials in patients with Type 2 diabetes demonstrated that combination therapy significantly lowered HbA1c by 1.34% and 1.21%, compared to a 0.54% reduction with placebo, starting from a baseline of 8.0%. These findings suggest that combination therapy may be especially beneficial in the liver transplant population, where patients often experience weight gain and develop metabolic co-morbidities
Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the surmount-4 randomized clinical trial
2016;11(6):e0157602
Here are the results: If I understand correctly, at some point 6 out of the 24 subjects in the placebo group stopped providing these records, and 3 out of 24 in the semaglutide group
How Lite Medical Clinic Can Help At Lite Medical Clinic, we take a comprehensive approach to your metabolic and cardiovascular health
Patients with contraindications - including personal or family history of medullary thyroid carcinoma or MEN 2 syndrome, pancreatitis history, severe GI or kidney disease, pregnancy, or breastfeeding - won't be approved